共抑制受体在银屑病中的研究进展
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R758.63

基金项目:

国家自然科学基金项目(81904210)


Research Progress of Co-inhibitory Receptors in Psoriasis
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目前银屑病的发病机制尚不明确,随着对于机制研究的不断深入,生物制剂作为治疗的新手段以其独有的优势正逐步应用于临床,其中针对共抑制受体的靶向药物在治疗多种疾病中取得显著疗效。中医治疗银屑病具有显著优势,其作用于人体具有多途径多靶点的特征。本文就共抑制受体在银屑病相关方面的研究进展进行综述,以期对银屑病中共抑制受体的靶向治疗提供依据,同时为中医药治疗银屑病的研究和应用提供新思路。

    Abstract:

    Abstract:At present, the pathogenesis of psoriasis is not clear. With the deepening of mechanism research, biological agents, as a new method of treatment, are gradually applied to clinic with their unique advantages. Among them, targeted drugs targeting co- inhibitory receptors have achieved remarkable curative effects in the treatment of a variety of diseases. Traditional Chinese medicine has significant advantages in the treatment of psoriasis. Its effect on the human body has the characteristics of multi- channel and multi- target. This paper reviews the research progress of co- inhibitory receptors in psoriasis, in order to provide basis for the targeted treatment of co-inhibitory receptors in psoriasis, and provide new ideas for the research and application of traditional Chinese medicine in the treatment of psoriasis.

    参考文献
    相似文献
    引证文献
引用本文

刘宇超,白彦萍,王磊.共抑制受体在银屑病中的研究进展[J].新中医,2022,54(3):16-20

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-02-14
  • 出版日期:
文章二维码